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Abstract
Urticaria is a common dermatological condition that can occur in acute and chronic forms. 
Common urticaria is generally easy to diagnose; however, urticarial syndromes should be 
considered in cases where lesions persist for greater than 24–36 h, the location of lesions 
has bilateral symmetry, urticarial lesions are accompanied by additional elementary lesions, 
and/or the patient presents with additional systemic symptoms. Additionally, urticarial syn‐
dromes should be considered for patients with typical urticarial lesions that do not respond 
to systemic antihistamine treatment. Hyperpigmentation or bruising can be observed fol‐
lowing resolution of urticarial syndromes. Many cutaneous and systemic diseases can 
cause urticarial syndromes. Systemic causes of urticarial syndromes can affect multiple 
organ systems and may be accompanied by systemic symptoms such as fever, asthenia, and 
arthralgia. Clinicopathologic correlation is essential for the accurate diagnosis of urticarial 
syndromes. In this chapter, cutaneous and systemic etiologies of urticarial syndromes are 
reviewed.
Keywords: urticaria, common urticaria, urticarial syndromes, cutaneous urticarial 
syndromes, systemic urticarial syndromes
1. Introduction
Urticaria is a disease with a lifetime prevalence of 25–30% and is characterized by itchy 
 urticarial lesions and/or angioedema [1, 2]. Although its physiopathology is not well under‐
stood, cutaneous mast cells are the main causative factor that is responsible for the release of 
histamine and other mediators [3, 4]. The disease is divided into acute and chronic depending 
on whether the duration is less or more than 6 weeks. While acute urticaria is often limited 
and the cause can be determined in most patients, chronic urticaria is a long‐term disease, and 
further investigation is required in terms of accompanying disorders or autoimmunity [5]. The 
diagnosis of common urticaria is usually made easily. However, some difficulties in terms 
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of response to treatment, accompanying lesions, and systemic findings can be seen in some 
patients. Various disorders, both cutaneous and systemic, are included in the spectrum called 
urticarial syndrome (Table 1). In general, lesions lasting longer than 24–36 h, showing bilat‐
eral symmetric involvement, with elementary lesions other than urticaria and accompanying 
systemic symptoms should bring urticarial syndromes to mind. Clinicopathologic correlation 
is essential in the diagnosis of urticarial syndromes [1, 5]. Cutaneous and systemic disorders 
that may cause the urticarial syndrome will be reviewed in this section.
2. Cutaneous urticarial syndromes
Various skin disorders can cause urticarial lesions and can be confused with common urticaria.
2.1. Urticarial dermatitis
Urticarial dermatitis is a clinical picture where urticarial plaques and edematous lesions are 
combined and is usually seen in the elderly. Urticarial dermatitis is quite itchy and often 
Cutaneous urticarial syndromes Systemic urticarial syndromes
Urticarial dermatitis Vasculitides
• Urticarial vasculitis
• Other vasculitides
Contact dermatitis
Papular urticaria
Mastocytosis Immunologic disorders
• Connective tissue diseases
• SLE, Sjogren syndrome, dermatomyositis
• Juvenile rheumatoid arthritis
Exanthematous drug eruption
Autoimmune bullous disorders
• Bullous pemphigoid
• Gestational pemphigoid
• Linear IgA dermatosis
• Dermatitis herpetiformis
• Epidermolysis bullosa acquisita
Hematologic diseases
• Waldenstrom macroglobulinemia
• Schnitzler syndrome
• Hypereosinophilic syndromes
• Polycythemia vera
• Non‐Hodgkin lymphoma (B cell)
Pruritic urticarial papules and plaques of pregnancy
Rare cutaneous urticarial syndromes
• Autoimmune progesterone/estrogen dermatitis
• Wells syndrome
• Interstitial granulomatous dermatitis
• Neutrophilic eccrine hidradenitis
• Urticaria‐like follicular mucinosis
Autoinflammatory syndromes
• Hereditary periodic fever syndromes
• Cryopyrin‐associated periodic syndromes
• Other autoinflammatory syndromes
Table 1. Cutaneous and systemic urticarial syndromes.
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characterized by diffuse and symmetrical involvement of the body and proximal  extremities. 
Facial and palmoplantar region involvement is usually not present. Existing lesions may 
 persist for days or even weeks. Excoriations and lichenification due to the severe itching may 
be observed in time. It usually has a chronic relapsing course and spontaneous regression is 
very rare [5, 6]. Most pathologists describe urticarial dermatitis as a “dermal hypersensitivity 
reaction.” Papillary dermal edema and minimal epidermal spongiosis with superficial peri‐
vascular lymphocytic and eosinophilic infiltration are seen on histopathologic examination 
[6, 7]. While the etiologic agents most commonly held responsible are drugs, detecting the 
triggering agent can sometimes be difficult [6]. Low to moderate doses of systemic steroids 
can provide relief in patients’ resistant to topical steroids and systemic antihistamines [5, 8].
2.2. Contact dermatitis
Contact dermatitis (CD) develops after contact with allergic and/or irritant agents and is fairly 
common. The sensitizers that most commonly cause allergic CD are poison ivy, nickel, form‐
aldehyde, and fragrances that are included in many cosmetics. Irritant CD is also called non‐
immunologic contact dermatitis and is most commonly due to fragrances, flavoring agents, 
and preservatives [9–11]. While CD usually causes itchy eczematous lesions, urticarial lesions 
may rarely be seen due to dermal edema. The border between CD and contact urticaria is not 
clear. Dermal edema is seen more commonly in contact urticaria, and this is accepted as the 
most important difference with CD. Histopathologic investigation is usually not required in 
CU as it develops in the region that contacts the allergic and/or irritant agent. However, if 
performed, a spongiotic dermatitis picture characterized by a mixed inflammatory infiltrate 
formed of lymphocytes, histiocytes, and eosinophils is often observed in CD. Only dermal 
changes are seen in CU and epidermal spongiosis is not seen [12, 13]. A patch test and/or 
 specific IgE investigation is recommended to detect the agent causing the problem.
2.3. Papular urticaria
Papular urticaria is a kind of allergic hypersensitivity reaction developing after arthropod 
bites. It is most common in children at the age of 2–10 years [14]. It usually develops in open 
regions of the body such as the arms, lower leg, and face due to insect bites from fleas, mos‐
quitoes, or bedbugs especially in the summer [15]. The genital, perianal, and axillary regions 
are generally protected. Vesicles, excoriation, and post‐inflammatory hyperpigmentation can 
be gradually observed in the middle of the lesion that starts as an itchy papule. Mostly, acute‐
type localized insect bites have urticarial features [16]. Diagnosis is usually clinical but can 
rarely be confused with other disease such as varicella, miliaria rubra, and Gianotti‐Crosti 
syndrome [17]. Nonsedating antihistamines and moderate‐potency topical corticosteroids for 
itching are usually adequate for treatment [14].
2.4. Exanthematous drug eruptions
Exanthematous drug eruptions, also called morbilliform or maculopapular drug  eruptions, 
are the most common drug hypersensitivity reaction [18]. They are present in form of 
 erythematous fixed macules, papules, or wheal‐like lesions with a bilateral and symmetrical 
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 distribution especially on the body after an average of 1 week following drug administration. 
The lesions become confluent in time and improve by leaving transient hyperpigmentation 
while regressing [5]. The mucous membranes are usually not involved. However, the mucous 
membranes (oral, conjunctival, nasal, or anogenital) and skin appendages (hair and nails) 
may be involved in patients with severe drug eruption. Mild fever can be seen. The medica‐
tion history is essential in the diagnosis. Histopathologic diagnosis is not always required. 
Biopsy sometimes does not help in the diagnosis because it does not contain specific signs. 
Skin biopsy is generally recommended in the case of drug use that may cause a drug erup‐
tion, fever >38°C, and the presence of erythroderma, blisters, and purpura or pustules and 
mucous membrane involvement [19]. Discontinuing the suspected drug immediately is 
 recommended in the treatment. Topical corticosteroids and systemic antihistamines are rec‐
ommended for symptomatic treatment. However, short‐term moderate‐high dose (predni‐
sone 1–2 mg/kg/day) systemic corticosteroid treatment can be recommended in those with a 
severe  exanthematous drug reaction [20].
2.5. Cutaneous mastocytosis (Urticaria pigmentosa)
Mastocytosis is a group of disorders characterized by the accumulation of mast cells in one 
or more organs. It is divided into two main groups as cutaneous and systemic [21]. Urticaria 
pigmentosa (UP) is the most common type of cutaneous mastocytosis both in childhood and 
adulthood. It presents with brown macules and papules, especially in the trunk or limbs. 
However, it can be seen as an urticarial rash that can affect the entire body in children. 
Dermographism‐urticaria (Darier finding) development after skin rubbing is present in most 
cases [21, 22]. Healing is usually with post‐inflammatory hyperpigmentation. The number 
of lesions is variable. The most common symptoms are itching and flushing. However, bulla 
development, recurrent syncope, and even anaphylaxis can be seen. Regression in symp‐
toms is seen in the majority of the patients until adolescence with full improvement in 50% 
[23]. Although clinicopathologic correlation is recommended for the diagnosis, histopatho‐
logic characteristics may not always be obvious. The treatment is usually symptomatic in 
 children. Phototherapy is the primary treatment in widespread maculopapular lesions seen 
in adults [24].
2.6. Autoimmune bullous disorders
Bullous pemphigoid, gestational pemphigoid, linear IgA dermatosis, and epidermolysis  bullosa 
acquisita are disorders due to autoantibodies toward various basal membrane components 
and characterized by subepidermal bulla formation related to these antigens. Another  common 
characteristic of these disorders is the possibility of urticarial lesions.
2.6.1. Bullous pemphigoid
Bullous pemphigoid (BP) is an autoimmune bullous disorder that is especially observed in 
elderly people and often accompanied by severe itching. It presents with tense bullae follow‐
ing a prodromal stage lasting weeks or even months. Bulla development may not be observed 
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in some patients. Pruritic eczematous and papular or urticaria‐like skin lesions are commonly 
observed in the prodromal period [25–27]. They may develop on a non‐inflammatory base or 
an urticarial‐erythematous base [28]. The body, extremity flexures, and axillary and inguinal 
folds are the main regions involved. Bilateral symmetrical involvement is usually present 
[25, 26, 28]. BP may not be considered in patients with a long‐term prodromal period. The 
gold standard in the diagnosis is histopathology and direct immunofluorescence. Detection 
of autoantibodies in the serum with indirect immunofluorescence has become the standard 
for the diagnosis at many centers [29].
2.6.2. Gestational pemphigoid
Gestational pemphigoid is a rare autoimmune skin disorder seen during pregnancy. It is 
 characterized by a severe itchy and bullous eruption due to damage in the basement 
 membrane of the skin by autoantibodies developing against placental BP180 (BPAG2/ 
collagen XVII) [30]. However, urticarial and eczematous lesions may be seen before and/or 
during bulla development in some cases. The onset is usually with severe itching around the 
belly. Red papules, urticarial plaques, or erythema multiforme‐like targetoid lesions develop. 
However, cases where the urticarial or targetoid lesions lasted longer have also been reported. 
Histopathology, direct immunofluorescence, and indirect immunofluorescence are important 
in the diagnosis [5, 29, 31].
2.6.3. Linear IgA bullous dermatosis
Linear IgA bullous dermatosis (LABD) is a mucocutaneous autoimmune subepidermal vesic‐
ulobullous disorder. Although the etiopathogenesis is not fully known, it is thought to be 
associated with drugs, infections, autoimmune diseases, gastrointestinal diseases, and malig‐
nancies [32, 33]. There can be clear or hemorrhagic lesions, tense vesicles, or bullae appearing 
on an erythematous or urticarial base [34]. When erythematous or urticarial lesions last a long 
time, the diagnosis of bullous disorders can be missed. The diagnosis is made with clinical, 
histopathologic, and immunologic data as in other autoimmune disorders.
2.6.4. Epidermolysis bullosa acquisita
Epidermolysis bullosa acquisita (EBA) is a rare acquired, chronic subepidermal bullous dis‐
ease of the skin and mucous membranes. It is characterized by antibodies developing against 
type VII collagen, which is the major component of anchoring fibrils. Clinical presentation is 
usually in the form of non‐inflammatory bullous lesions that improve with scarring and milia 
formation in trauma‐prone acral regions. However, in addition to the classic presentation, 
BP‐like presentation, cicatricial pemphigoid‐like presentation, Brunsting‐Perry pemphigoid 
presentation, and LABD‐like disease can also be seen. Urticarial lesions can be observed with 
various durations, especially with a BP‐like and LABD‐like presentation. Clinical, histopatho‐
logic, and immunologic investigations are required in the diagnosis. Colchicine, dapsone, 
plasmapheresis, photopheresis, infliximab, and intravenous immunoglobulin are the most 
commonly used treatment agents. However, treatment satisfaction is usually low [5, 35].
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2.7. Pruritic urticarial papules and plaques of pregnancy
Pruritic urticarial papules and plaques of pregnancy (PUPPP) is the itchiest dermatosis of 
pregnancy. PUPPP is seen in the form of erythematous, urticarial plaques, and papules and 
usually starts from the abdomen and extends to the thighs, legs, back, buttocks, arms, and 
breasts. However, the periumbilical region is protected. The lesions usually regress within 6 
weeks in the postpartum period [36, 37]. In addition to erythematous and urticarial plaques, 
targetoid and vesicular lesions can be seen in approximately half of the patients as the disease 
progresses. Moisturizers, topical corticosteroids, and antihistamines can be recommended for 
symptomatic relief in patients with severe itching [36].
2.8. Rare cutaneous urticarial syndromes
Autoimmune progesterone/estrogen dermatitis, interstitial granulomatous dermatitis, eosin‐
ophilic cellulitis (Wells syndrome), neutrophilic eccrine hidradenitis (NEH), and urticaria‐like 
follicular mucinosis are rare cutaneous urticarial syndromes.
2.8.1. Autoimmune progesterone/estrogen dermatitis
Autoimmune progesterone dermatitis (APD) is a rare dermatosis that causes  inflammation 
at the luteal phase of the menstrual cycle and presents with several skin findings. Skin 
signs include urticarial, eczematous and vesiculopustular eruption, targetoid lesions, and 
 angioedema [38, 39]. Urticaria is seen in about half of patients [5]. There is no specific 
 diagnostic test. A history of premenstrual exacerbation, prevention of lesions with ovulation 
inhibition, and a positive reaction to intradermal progesterone injection are helpful in the 
diagnosis [39]. Autoimmune estrogen dermatitis has also been identified in the literature but 
only in low numbers [5].
2.8.2. Interstitial granulomatous dermatitis
Interstitial granulomatous dermatitis (IGD) is a rare dermatosis and accepted as a separate 
histopathologic entity [40]. Papules, nodules, plaques, and an urticarial rash can be observed 
in the disorder that is more common in women and the elderly people. Of the cases identified 
until today, two‐thirds have had a chronic course and the remaining a recurrent and episodic 
course. Recognizing IGD is quite important in order to indicate the underlying autoimmune 
disorders [5, 40]. Clinicopathological correlation is essential for the diagnosis.
2.8.3. Wells syndrome (eosinophilic cellulitis)
Wells syndrome is a rare dermatosis that presents as acute, recurrent, itchy, erythematous, 
and edematous lesions [41]. Although it brings bacterial cellulitis to mind first in the clinic, 
not responding to systemic antibiotics is an important indicator in the diagnosis. Another 
 differential diagnosis is urticaria due to the presence of urticarial lesions. In addition to  bacterial 
cellulitis and urticaria, it can be confused with insect bite, contact dermatitis,  angioedema, and 
hypereosinophilic syndrome [42]. Clinicopathologic correlation is important in the diagnosis. 
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Dermal edema, eosinophilic dermal infiltration, and free eosinophilic granules coating collagen 
bundles (“flame figures”) are observed histopathologically. However, the histopathologic 
signs change in time. Peripheral eosinophilia may also be present in the acute phase [41, 42].
2.8.4. Neutrophilic eccrine hidradenitis
Neutrophilic eccrine hidradenitis (NEH) is a very rare dermatosis seen in patients with malig‐
nancy or those receiving chemotherapy. The majority of the cases are acute myelogenous 
leukemia patients receiving chemotherapy [43]. It clinically presents with fixed erythematous 
and edematous papules and plaques. It is usually accompanied by fever. Histopathologic 
signs are important in the diagnosis. It is histopathologically characterized by neutrophilic 
infiltration accompanied by necrosis around eccrine glands and secretory coils. No specific 
treatment is required as it is usually self‐limiting. However, systemic corticosteroid treatment 
has been reported to shorten the duration of the lesions and the fever [5, 44].
2.8.5. Urticaria‐like follicular mucinosis
Urticaria‐like follicular mucinosis (ULFM) is a very rare disease that presents with itching, 
urticarial papules, and plaques on an erythematous base, usually in the head and neck. It is 
usually seen in middle‐aged men. Spontaneous improvement is common. However, recur‐
rence can be seen. Histopathological characteristics are important in the diagnosis. Cystic 
spaces filled with mucin in the outer sheath of hair follicles are histologically seen [45].
3. Systemic urticarial syndromes
In addition to skin disorders, many systemic diseases can cause urticarial lesions. The differen‐
tial diagnosis with ordinary urticaria should consider that systemic urticarial syndromes may 
cause elementary skin lesions such as papules, vesicles, hemorrhages, necrosis, and crusts in 
addition to urticarial skin lesions and also many systemic symptoms such as fever,  asthenia, 
and arthralgia. Lesions usually last longer than 24–36 h, show bilateral and  symmetrical 
 distribution, and recover with hyperpigmentation and bruising [46, 47]. Systemic diseases 
causing urticarial skin lesions will be reviewed in this section.
3.1. Vasculitides
3.1.1. Urticarial vasculitis
Urticarial vasculitis (UV) is a separate clinicopathologic entity characterized by recurrent 
urticarial episodes, histopathologically showing leukocytoclastic vasculitis characteristics 
[48]. It is the most common clinical picture causing systemic urticarial syndrome. UV has 
been reported in 2–20% of the patients diagnosed with chronic urticaria [49]. It causes  painful 
and burning skin lesions rather than itching. Urticarial lesions continue longer than 24–36 h. 
Central clearing of lesions is seen in time and they are accompanied by palpable purpura. 
Necrosis and ulceration are less common skin findings [50]. The lesions regress with a residual 
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hyperpigmentation [47, 51]. Histopathology is essential in the diagnosis. The correct choice of 
the lesion is important in order to reveal true vasculitic changes. Leukocytoclastic vasculitis 
of the small dermal vessels characterized by a neutrophilic perivascular infiltrate, the typical 
findings for UV, is observed in fully developed lesions. Additionally, neutrophil fragmenta‐
tion, nuclear dust, erythrocyte extravasation, and fibrin deposition in and around the vessels 
are observed [50, 52].
Urticarial vasculitis is mostly idiopathic. However, an association with various drugs, sun, 
cold, connective tissue diseases, infections, and various malignancies (paraneoplastic) has 
been identified [50, 51, 53]. Among connective tissue diseases, it is most commonly seen with 
systemic lupus erythematosus (SLE) [53]. The most common laboratory findings in idiopathic 
UV are elevation of the erythrocyte sedimentation rate and reduction of serum complement 
levels [48]. UV is divided into two groups as mainly normocomplementemic UV (NUV) and 
hypocomplementemic UV (HUV), based on complement levels [51, 54]. Systemic involvement 
is usually absent or minimal and the prognosis is better in NUV patients. However, there is a 
propensity to more severe multi‐organ involvement in HUV patients [48]. The most common 
systemic manifestations are in the joints, kidneys, and lungs [52, 54]. Gastrointestinal and 
neurologic involvement can also be seen [50, 52]. Antinuclear antibody (ANA) positivity has 
also been reported in up to 78% of HUV patients [52, 54].
Several agents are used for UV treatment and the treatment response is variable. Systemic 
corticosteroids are the basis of the treatment in UV where antihistamines are usually not suf‐
ficient. UV can be controlled with prednisone at a dose of 1 mg/kg/day but can recur after the 
dose is decreased. Steroid‐sparing agents are used in the treatment to avoid the side effects of 
long‐term corticosteroids. Dapsone, colchicine, hydroxychloroquine, mycophenolate mofetil, 
interferon‐alpha, cyclosporine A, azathioprine, cyclophosphamide, rituximab, intravenous 
immunoglobulins, anakinra, and plasmapheresis are treatment agents that can be used alone 
or in combination with corticosteroids [50–52].
3.1.2. Other vasculitides
Urticarial lesions can be seen in the Churg‐Strauss syndrome, Wegener granulomatosis, and 
polyarteritis nodosa, which are characterized by vasculitis.
The Churg‐Strauss syndrome is a rare allergic granulomatous polyangiitis that usually affects 
middle‐aged men. The most common sign is asthma. However, hay fever, rash, gastrointes‐
tinal bleeding, and pain can also be seen. Urticarial lesions have been identified in less than 
10% of the patients [55].
Polyarteritis nodosa (PAN) is a vasculitis affecting medium‐sized vessels and is very rare. 
Although it can affect any tissue in the body, it most commonly affects the muscles, joints, 
 intestines, nerves, and skin. Urticarial lesions have been identified in about 6% of PAN 
patients [56].
3.2. Immunologic disorders
Many immunologic disorders can cause urticarial lesions. Connective tissue diseases and 
mainly SLE, Sjogren syndrome, dermatomyositis, and mixed connective tissue disease are 
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important among these. It is important to know that urticarial lesions can also be seen in addi‐
tion to the existing lesions in connective tissue diseases. Although rare, urticarial lesions can 
also be present in juvenile rheumatoid arthritis [51].
3.3. Hematologic diseases
A wide variety of hematologic diseases can cause urticarial lesions.
3.3.1. Schnitzler syndrome
Schnitzler syndrome is characterized by an urticarial rash and monoclonal gammopathy 
 clinically and neutrophil‐mediated inflammation histologically [57]. An urticarial rash and 
usually IgM but rarely IgG monoclonal gammopathy are present with a chronic pattern in 
all the patients. Recurrent fever, bone or joint pain, increased bone density, hepato‐ or sple‐
nomegaly, lymphadenopathy, and elevated acute‐phase reactants are also accepted as minor 
criteria [58]. Approximately, 300 cases have been identified in the literature [57]. Risk of devel‐
oping a lymphoproliferative disorder at an approximate rate of 15% has been reported in the 
10‐year follow‐up, although the syndrome usually has a benign course. The most commonly 
developing lymphoproliferative disease is Waldenstrom macroglobulinemia. Treatment is 
usually unsatisfactory, but high doses of corticosteroids, systemic antihistamines, oral cyclo‐
sporine, intravenous pulse cyclophosphamide, and pefloxacin mesylate are the therapeutic 
agents used [58].
3.3.2. Waldenstrom macroglobulinemia
Waldenstrom macroglobulinemia is a chronic indolent lymphoproliferative disorder [59]. 
Increased levels of IgM paraprotein in the circulation and infiltration of the bone marrow with 
lymphocytes and plasma cells are seen. Urticarial lesions can be seen in addition to purpura, 
edema, and ulceration [60].
3.3.3. Hypereosinophilic syndromes
This is a group of myeloproliferative disorders characterized by multiple organ damage 
caused by persistent eosinophilia. It is more common in young and middle‐aged patients but 
can be seen at any ages. Their classification is complicated. Three factors are mainly included 
in the diagnostic criteria. These are eosinophilia longer than 6 months (>1500/μl), no iden‐
tifiable etiology for eosinophilia, and signs and symptoms of organ involvement. The most 
commonly involved organs are the skin, heart, lungs, and the central and peripheral nervous 
systems. Skin findings are usually common and are in the form of eczematous, urticarial, and 
angioedema‐like findings [61, 62].
3.4. Autoinflammatory syndromes
Autoinflammatory syndromes are a group of heterogeneous single‐gene disorders  causing 
recurrent febrile episodes and inflammatory cutaneous, mucosal, serosal, and osteoarticular 
Urticarial Syndromes
http://dx.doi.org/10.5772/67993
125
manifestations [63, 64]. No infectious, autoimmune, or neoplastic reason has been shown. 
Excessive activation of the interleukin 1 beta (IL‐1β) pathway is most commonly held 
 responsible in the etiopathogenesis [64].
Many syndromes such as familial Mediterranean fever (FMF), Tumor necrosis factor (TNF) 
receptor‐associated periodic syndrome, hyperimmunoglobulinemia D with periodic fever 
syndrome (HIDS), and cryopyrin‐associated periodic syndromes have been identified among 
the autoinflammatory syndromes. A monogenic defect has been found but only in some of 
these  disorders. However, all have been included within the autoinflammatory syndromes as 
they show  similar inflammatory features [63].
Autoinflammatory syndromes mostly start in infancy or during childhood. Although most 
cases are familial, some are sporadic. Recurrent episodes of inflammation with fever, eleva‐
tion in acute‐phase reactants, and skin rash can be seen in the absence of an infectious or auto‐
immune etiology. Although joint and skin involvement can be seen in various forms, fever is 
almost always present. These symptoms can also be accompanied by systemic findings such 
as abdominal pain, myalgia, ocular involvement, serositis, amyloidosis, and  neurological 
signs [63, 65].
The skin signs show variety. Urticarial lesions are the predominant skin signs, especially 
in cryopyrinopathies, and occur in the first year of life. They are more commonly seen as 
 erysipelas‐like plaques in the lower extremities in FMF. Erythematous macules and urticarial 
lesions are seen in HIDS [51, 65].
Autoinflammatory disorders can pose a significant challenge for primary care physicians, 
pediatricians, dermatologists, rheumatologists, and infectious disease specialists in terms of 
wide‐ranging clinical spectrum. A perivascular and interstitial neutrophil‐rich infiltration 
suggesting neutrophilic urticarial dermatoses is observed in the histopathologic evaluation 
of skin lesions. Leukocytoclastic vasculitis‐like signs can also be seen [65, 66]. However, these 
signs are not specific. The diagnosis of autoinflammatory disorders is usually made with the 
clinical features and then supported by either genetic testing or the patient’s response to IL‐1 
inhibition or other specific therapies [63].
4. Conclusion
Ordinary urticaria is a clinical picture frequently encountered by dermatologists and usu‐
ally presents no diagnostic difficulty. However, cutaneous and systemic urticarial syndromes 
should be considered in the case of persistence of urticarial lesions, bilateral and symmetri‐
cal location, healing with hyperpigmentation or bruising, the presence of other elementary 
lesions, not responding to systemic antihistamines, and being accompanied by systemic find‐
ings. The differential diagnosis of ordinary urticaria and urticarial syndromes is not easy. 
A detailed clinical evaluation should therefore be performed. Clinicopathologic correlation 
and, if necessary, further studies should be conducted in the presence of findings suggesting 
urticarial syndromes.
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